Peter B. Silverman J.D. Net Worth

The estimated Net Worth of Peter B. Silverman is at least $1.12 Million dollars as of 27 June 2024. Mr Silverman owns over 10,000 units of Merus N.V stock worth over $502,800 and over the last 5 years he sold MRUS stock worth over $0. In addition, he makes $614,879 as Exec. VP, Gen. Counsel und Chief Intellectual Property Officer and Head of Utrecht & US Legal at Merus N.V.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr D MRUS stock SEC Form 4 insiders trading

Mr has made over 4 trades of the Merus N.V stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of MRUS stock worth $179,400 on 27 June 2024.

The largest trade he's ever made was exercising 62,000 units of Merus N.V stock on 17 June 2024 worth over $1,510,320. On average, Mr trades about 14,035 units every 76 days since 2020. As of 27 June 2024 he still owns at least 10,000 units of Merus N.V stock.

You can see the complete history of Mr Silverman stock trades at the bottom of the page.

Mr. Peter B. Silverman J.D. biography

Peter B. Silverman J.D. is the Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal at Merus N.V.

What is the salary of Mr D?

As the Exec. VP, Gen. Counsel und Chief Intellectual Property Officer and Head of Utrecht & US Legal of Merus N.V, the total compensation of Mr D at Merus N.V is $614,879. There are 2 executives at Merus N.V getting paid more, with Hui Liu having the highest compensation of $1,382,530.

How old is Mr D?

Mr D is 43, he's been the Exec. VP, Gen. Counsel und Chief Intellectual Property Officer and Head of Utrecht & US Legal of Merus N.V since . There are 15 older and 1 younger executives at Merus N.V. The oldest executive at Merus N.V is Gregory Perry, 59, who is the Independent Non-Executive Vice Chairman of the Board.

What's Mr D's mailing address?

Peter's mailing address filed with the SEC is C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, P7, 3584 CT.

Insiders trading at Merus N.V

Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... und Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.

What does Merus N.V do?

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Complete history of Mr Silverman stock trades at Merus N.V

Merus N.V executives and stock owners

Merus N.V executives and other stock owners filed with the SEC include:

• Hui Liu,
  Chief Business Officer and Head of Merus U.S.
• Dr. Sven Ante Lundberg M.D.,
  CEO, Pres, Principal Financial Officer & Exec. Director
• Peter B. Silverman J.D.,
  Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal
• Hui Liu,
  Chief Bus. Officer, Exec. VP & Head of Merus U.S.
• Alexander Bakker,
  Chief Development Officer
• Peter Silverman,
  General Counsel, Chief Intellectual Property Officer and Head of US Legal
• John de Kruif,
  Chief Technology Officer
• Sven Lundberg,
  President, Chief Executive Officer, Principal Financial Officer, Executive Director
• Anand Mehra,
  Non-Executive Independent Chairman of the Board
• Andrew Joe,
  Chief Medical Officer
• Paolo Pucci,
  Non-Executive Independent Director
• Victor Sandor,
  Non-Executive Independent Director
• Jillian Connell,
  Investor Relations & Corporate Communications
• Leonard Kanavy,
  Non-Executive Independent Director
• Gregory Perry,
  Independent Non-Executive Vice Chairman of the Board
• Mark Iwicki,
  Non-Executive Independent Director
• Shannon Campbell,
  Exec. VP & Chief Commercial Officer
• Dr. Cecile A.W. Geuijen Ph.D.,
  Chief Scientific Officer
• Anne Noordzij,
  Sec.
• Dr. Ellen Broug,
  Exec. Director of IP & Sec.
• Dr. Andrew Joe M.D.,
  Chief Medical Officer
• Alexander Berthold Hendrik Bakker Ph.D.,
  Chief Devel. Officer & Sr. VP
• Cornelis Adriaan de Kruif Ph.D.,
  CTO & Sr. VP
• Dr. Hennie Hoogenboom,
  Co-Founder and Scientific Advisor
• Partners L P/Ilbiotechnolog...,
  
• Lex Bakker,
  SVP, Chief Development Officer
• Mark Throsby,
  EVP & Chief Scientific Officer
• Partners L P/Ilbiotechnolog...,
  
• Corp Incyte,
  10% owner
• Cecile A W Geuijen,
  SVP & Chief Scientific Officer
• Jason Haddock,
  
• Maxine Gowen,
  
• Len Kanavy,
  
• Harry Shuman,
  VP Controller, PAO
• Fabian Zohren,
  Chief Medical Officer